SHPG News Alert Shire Plc American Depositary Shares (SHPG) 208.76

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Shire Plc American Depositary Shares (SHPG) 208.76 $SHPG

Billionaires Are Loading Up On These 3 Stocks
Patrick Morris, The Motley Fool - Motley Fool - Tue Dec 16, 12:46PM CST
The numbers are in for what the 10 largest hedge funds in America have been buying, letting us see which three companies had the most wanted stock in the third quarter. According to the latest data from S&P Capital IQ and its Hedge Fund...
ACT: 256.52 (-6.48), SHPG: 208.76 (+0.28), ABBV: 65.25 (-0.37), BABA: 105.77 (+1.07)

BioTime Appoints Angus C. Russell to Board of Directors
Business Wire - Mon Dec 15, 7:38AM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors.
SHPG: 208.76 (+0.28), ITMN: 73.89 (-0.02), BTX: 3.20 (+0.04)

Additions/deletions from Nasdaq's Q-50 Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:54AM CST

GLNG: 31.44 (-1.83), MXIM: 30.48 (-0.16), ODFL: 76.21 (-1.19), NUAN: 13.81 (-0.22), UTHR: 126.04 (-2.81), FSLR: 40.90 (-0.76), QQQ: 99.98 (-1.63), ALNY: 92.08 (-1.87), SCTY: 49.77 (+0.13), SHPG: 208.76 (+0.28), MPEL: 22.21 (-0.94), EXPE: 86.04 (-1.29), FFIV: 128.27 (-1.99), SSYS: 79.07 (-4.84), CAR: 55.83 (-1.76), JD: 23.13 (-0.13), SPLK: 53.75 (-1.12), MELI: 127.00 (-7.28), MEOH: 44.22 (+0.99), CREE: 30.03 (-0.24)

Quarterly Changes to the NXTQ Index
GlobeNewswire - Mon Dec 15, 6:20AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, December 22, 2014.
MXIM: 30.48 (-0.16), ODFL: 76.21 (-1.19), EA: 45.45 (unch), UTHR: 126.04 (-2.81), ALNY: 92.08 (-1.87), SCTY: 49.77 (+0.13), SHPG: 208.76 (+0.28), SSYS: 79.07 (-4.84), FFIV: 128.27 (-1.99), MPEL: 22.21 (-0.94), AAL: 47.96 (-2.88), CAR: 55.83 (-1.76), NWS: 14.24 (-0.01), MEOH: 44.22 (+0.99), CREE: 30.03 (-0.24), GLNG: 31.44 (-1.83), NUAN: 13.81 (-0.22), FSLR: 40.90 (-0.76), LRCX: 76.84 (-1.49), EXPE: 86.04 (-1.29), SPLK: 53.75 (-1.12), JD: 23.13 (-0.13), MELI: 127.00 (-7.28), NDAQ: 45.74 (-0.72)

Tax Inversions In The U.S.: We Gotta Get Out Of This Place
Cornell Business Review - Seeking Alpha - Sun Dec 14, 1:12PM CST
By Hunter Bosson Following a summer filled with foreign mergers, tax inversions have become the innovative and morally dubious business practice of 2014. As American firms shift their headquarters overseas, widespread claims that a continued...
MDT: 71.34 (-0.65), COV: 99.74 (-0.30), SHPG: 208.76 (+0.28), ABBV: 65.25 (-0.37), BKW: 35.50 (-1.16)

This Tiny Biotech Worries Sanofi and Shire, and Vexes GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 8:28AM CST
Source: Amicus Therapeutics. Doctors may soon have a new therapy to use when treating patients with Fabry Disease, a rare genetic disease that can result in kidney failure. That's because emerging biotech stock Amicus Therapeutics plans to file...
SHPG: 208.76 (+0.28), GSK: 41.92 (+0.62), SNY: 45.38 (+0.98), FOLD: 7.73 (-0.15)

What Investors Can Learn From The Portfolios Of Fund Managers
Elite Wealth Management - at Seeking Alpha - Sun Dec 14, 4:47AM CST

MU: 32.92 (-0.43), ACT: 256.52 (-6.48), C: 51.17 (-1.62), COV: 99.74 (-0.30), CVI: 38.44 (+0.81), AET: 85.64 (-1.03), PCLN: 1,045.84 (-32.80), FDML: 15.24 (+0.08), TWX: 80.56 (-1.01), STAY: 18.30 (-0.28), HCA: 72.46 (-1.03), EBAY: 55.94 (+0.50), MRVL: 13.79 (-0.29), SUNE: 18.19 (+0.19), SHPG: 208.76 (+0.28), GLD: 114.95 (+0.56), GM: 30.73 (-0.27), IEP: 90.77 (-1.07), GOOGL: 498.16 (-17.68), TWC: 143.10 (-0.98), AIG: 52.88 (-0.60), AAPL: 106.75 (-1.47)

Shire Updates on Pipeline at Research & Development Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:43AM CST
Shire plc (SHPG) hosted its research and development (R&D) Day and provided key updates on its pipeline.
VRX: 136.92 (-1.24), SHPG: 208.76 (+0.28), SCMP: 12.89 (+0.23), ABBV: 65.25 (-0.37)

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 102.76 (-1.20), SHPG: 208.76 (+0.28), SLXP: 110.11 (+7.08)

Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 108.79 (-1.47), ENDP: 67.73 (+0.46), BDX: 134.04 (-1.71), MDT: 71.34 (-0.65), COV: 99.74 (-0.30), ITMN: 73.89 (-0.02), BMY: 57.69 (-0.86), GSK: 41.92 (+0.62), JNJ: 102.76 (-1.20), CBST: 96.73 (+0.42), CFN: 58.65 (-0.07), SHPG: 208.76 (+0.28), AUXL: 32.75 (-0.01), ABBV: 65.25 (-0.37), IDIX: 24.50 (+0.05), SYK: 90.78 (-0.62), NVS: 91.65 (+0.01)

Notes from Shire's Investor Day: $10B by 2020
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 9:51AM CST

SHPG: 208.76 (+0.28)

Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020
PR Newswire Europe - Wed Dec 10, 6:01AM CST
LEXINGTON, Massachusetts, December 10, 2014 /PRNewswire/ --
SHPG: 208.76 (+0.28)

Cystic Fibrosis Foundation Therapeutics Announces $15 Million Research Collaboration with Shire for Development of Novel CF Treatment
PR Newswire - Wed Dec 10, 5:55AM CST
Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
SHPG: 208.76 (+0.28)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $500,000 From Investment In Shire plc To Contact Brower Piven For More Information
Business Wire - Tue Dec 09, 8:50PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of Shire plc ("Shire" or the "Company" (Nasdaq: SHPG) American Depository Shares or purchased call options or sold put options of Shire between June 20, 2014 and October 14, 2014, inclusive (the "Class Period" .
SHPG: 208.76 (+0.28)

Roof Leaker To Watch: Shire (SHPG)
at The Street - Tue Dec 09, 10:40AM CST
Trade-Ideas LLC identified Shire (SHPG) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
SHPG: 208.76 (+0.28)

This Could Be the Next Big Pharma Buyout
Motley Fool Staff - Motley Fool - Mon Dec 08, 9:05AM CST
In a bid to offset the risk of patent expiration, drugmakers spend billions of dollars every year on acquisitions to bolster drug pipelines and boost sales. But just because we know that Big Pharma has a penchant for purchases doesn't mean we know...
ZTS: 40.85 (-0.89), MDVN: 102.50 (-1.58), VRX: 136.92 (-1.24), SHPG: 208.76 (+0.28), PFE: 30.67 (-0.19), LLY: 69.26 (-0.41), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86)

Zacks Industry Outlook Highlights: AbbVie, Shire, Medtronic and Walgreen
PR Newswire - Mon Dec 08, 8:30AM CST
Today, Zacks Equity Research discusses the Medical Tech, including AbbVie Inc. (NYSE:ABBV-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Medtronic Inc. (NYSE:MDT-Free Report) and Walgreen Co. (NYSE:WAG-Free Report).
MDT: 71.34 (-0.65), SHPG: 208.76 (+0.28), ABBV: 65.25 (-0.37)

Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Mon Dec 08, 4:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 5. Ulta Salon (NASDAQ: ULTA ) Is Looking Good Ulta Salon ( ULTA ) was up on Friday, and Cramer recalled a time when it seemed management was...
RH: 95.09 (+0.09), UTX: 113.23 (+1.32), CAH: 79.10 (-0.47), AMGN: 159.44 (-0.16), DIS: 90.17 (-0.73), AZO: 597.93 (-7.91), GILD: 100.46 (-2.70), SHPG: 208.76 (+0.28), COST: 137.31 (-0.88), ABBV: 65.25 (-0.37), AGIO: 107.47 (-3.76), DOV: 68.79 (+1.03), ULTA: 127.28 (-1.06), IDXX: 143.37 (-3.13), LE: 48.87 (+0.49), MBLY: 41.42 (+0.59)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 05, 7:22PM CST
Cramer will be watching for news from Agios Pharmaceuticals and Amgen and awaiting an explanation from United Technologies about its former CEO.
KMI: 38.07 (-0.21), RH: 95.09 (+0.09), UTX: 113.23 (+1.32), CAH: 79.10 (-0.47), HAL: 38.11 (+0.29), AMGN: 159.44 (-0.16), PAA: 46.81 (+1.43), SLB: 80.19 (+0.29), RFMD: 14.94 (+0.01), AZO: 597.93 (-7.91), GILD: 100.46 (-2.70), S: 3.81 (-0.24), SHPG: 208.76 (+0.28), COST: 137.31 (-0.88), ABBV: 65.25 (-0.37), AGIO: 107.47 (-3.76), DOV: 68.79 (+1.03), ULTA: 127.28 (-1.06), IDXX: 143.37 (-3.13), LE: 48.87 (+0.49), CRM: 53.79 (-1.62)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 88

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading

Top 5 Most Recently Viewed Articles

Nukkleus Stock Skyrockets 16% After Major Decision

Updated Category News Views 330

Nukkleus Inc. Stock Soars in After-Hours Trading Nukkleus Inc. (NASDAQ: NUKK) is making headlines as its shares have surged during after-hours trading following important developments within the company. This noteworthy stock movement reflects both investor sentiment and strategic changes that the company is undergoing. After-Hours Rally Sparks Investor Interest In recent...

Continue Reading
Tambourine One Revolutionizes Hotel Booking Experiences

Updated Category News Views 135

Introducing Tambourine One: A New Era in Hotel Booking Tambourine, the renowned leader in hotel marketing technology, has launched an innovative product known as Tambourine One. This all-in-one solution merges their advanced website technology with a booking engine, aimed at boosting direct bookings for hotels and resorts. By enhancing the booking process, Tambourine One...

Continue Reading
Midwest Great Dane: A New Era for Trudell Trailer Sales

Updated Category News Views 217

Midwest Great Dane Reveals Brand Transformation Midwest Great Dane, previously known as Trudell Trailer Sales, is making waves in the transportation and trucking industry with its recent name change. This transformation stems from a strategic acquisition by Cox Automotive, aimed at enhancing their representation of the Great Dane brand in the Midwest. The organization's...

Continue Reading
SoftServe Launches New Partner Unit to Boost AI Solutions

Updated Category News Views 334

SoftServe Unveils New Partner Business Unit for Enhanced AI Services SoftServe has officially launched its first dedicated Partner Business Unit (BU), marking a significant step forward in its strategic partnership with Microsoft. This initiative is designed to leverage SoftServe's extensive experience in technology and digital services, ensuring that organizations can...

Continue Reading
Portugal's Agri-Food Push in Canada: A Taste for Growth

Updated Category News Views 52

Eyeing Fresh Opportunities in Canada Here's a hot one for you—Portugal's agri-food sector is making a notable splash over in Canada. Yeah, you heard it right. Amidst the hustle and bustle of the SIAL Canada, which isn't just any minor shindig, "Taste & Feel Portugal 2.0" aims to put Portugal's top-tier grub on the map. It's about more than nibbling on cheese; it's a...

Continue Reading